Effects of Sertraline Treatment for Young Children with FXS

Authors

Andrew Ligsay, MIND Institute, University of California, Davis
Laura Greiss Hess, Department of Occupational Therapy, Dominican University of CaliforniaFollow
Sarah Fitzpatrick, MIND Institute, University of California,DavisFollow
Kerrie Lemons Chitwood, MIND Institute, University of California,DavisFollow
Jonathan Polussa, MIND Institute, University of California,DavisFollow
Salpi Siyahian, MIND Institute, University of California,Davis
Randi Hagerman, MIND Institute, University of California,DavisFollow

Document Type

Conference Proceeding

Source

American Academy of Pediatrics (AAP) National Conference

Location

San Francisco, CA

Publication Date

10-2015

Department

Occupational Therapy

Abstract

Selective serotonin reuptake inhibitors (SSRIs) help treat many of the phenotypic manifestations of fragile X syndrome (FXS) including anxiety, sensory processing challenges, and communication and intellectual deficits. However, the efficacy of SSRIs has not been previously studied in children with FXS under five-years-old. The purpose of this study was to elucidate group differences in behavior and developmental outcome measures for young children with FXS when treated with sertraline compared to placebo.

Comments

Presented at the American Academy of Pediatrics (AAP) National Conference, San Francisco, CA